<DOC>
	<DOCNO>NCT00167817</DOCNO>
	<brief_summary>Patients schizophrenia much likely engage smoke addictive behavior , possibly related biochemical abnormality reward center brain . The primary purpose present study investigate whether switch patient schizophrenia new atypical antipsychotic , aripiprazole , drug novel mechanism action , impact smoking behavior .</brief_summary>
	<brief_title>Effect Switch Aripiprazole Health Smoking Parameters Patients With Schizophrenia : A Pilot Study</brief_title>
	<detailed_description>This 8 week open label trial conduct stable adult outpatient schizophrenia smoker . The primary intervention switch subject 's antipsychotic aripiprazole , flexibly dose 15-30 mg/day . The outcome measure include rating smoking behavior use Fagerstrom Test Nicotine Dependence , saliva cotinine obtain baseline endpoint . Secondary measure include weight , serum glucose lipid , rating symptom severity use PANSS , rating instrumental measure motor function . We anticipate enrol 25 subject obtain needed 15 completers week 8 endpoint .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Schizophrenia , stable antipsychotic dose least one month 2 . Ages 1865 inclusive 3 . Overweight ( body mass index 25 kg/m2 great ) 4 . Daily cigarette smoker ( selfreport ) 1 . Inability provide inform consent 2 . Treatment refractory schizophrenia 3 . Current treatment clozapine 4 . Current antipsychotic polypharmacy may preclude monotherapy aripiprazole 5 . Documented poor compliance oral antipsychotic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Smoking</keyword>
	<keyword>Metabolic</keyword>
	<keyword>Health</keyword>
	<keyword>Glucose</keyword>
	<keyword>Lipids</keyword>
</DOC>